Xtant Medical’s (XTNT) “Buy” Rating Reiterated at BTIG Research

BTIG Research reiterated their buy rating on shares of Xtant Medical (NYSEAMERICAN:XTNT) in a report published on Wednesday,Benzinga reports. They currently have a $1.00 price objective on the medical device company’s stock.

Separately, Craig Hallum reissued a “buy” rating on shares of Xtant Medical in a research note on Wednesday, March 18th. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $1.00.

Xtant Medical Price Performance

Shares of XTNT stock opened at $0.46 on Wednesday. The stock’s fifty day simple moving average is $0.54 and its 200 day simple moving average is $0.63. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.34 and a quick ratio of 1.63. The firm has a market cap of $63.94 million, a price-to-earnings ratio of 45.64 and a beta of -0.11. Xtant Medical has a one year low of $0.44 and a one year high of $0.95.

Xtant Medical (NYSEAMERICAN:XTNT) last announced its quarterly earnings results on Wednesday, May 13th. The medical device company reported ($0.02) EPS for the quarter, meeting the consensus estimate of ($0.02). The business had revenue of $20.88 million for the quarter, compared to analyst estimates of $20.16 million. Xtant Medical had a return on equity of 3.68% and a net margin of 1.50%.

Hedge Funds Weigh In On Xtant Medical

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC lifted its stake in shares of Xtant Medical by 7.3% during the first quarter. Renaissance Technologies LLC now owns 987,410 shares of the medical device company’s stock valued at $551,000 after acquiring an additional 67,550 shares during the period. Wiregrass Investment Management LLC acquired a new position in shares of Xtant Medical during the fourth quarter valued at $81,000. Tradition Wealth Management LLC acquired a new position in shares of Xtant Medical during the fourth quarter valued at $79,000. Hillsdale Investment Management Inc. acquired a new position in shares of Xtant Medical during the fourth quarter valued at $284,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Xtant Medical during the fourth quarter valued at $220,000. Institutional investors and hedge funds own 69.33% of the company’s stock.

About Xtant Medical

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.